Aarey Drugs corrects FY25 Integrated Annual Report for typographical errors
The corrigendum addresses minor typographical errors in the annual report that do not affect the company's financial statements or operations, resulting in a low impact on investors.
The announcement clarifies typographical errors in the Integrated Annual Report, explicitly stating they do not impact financial statements, thus maintaining a neutral outlook.
Aarey Drugs & Pharmaceuticals Limited has issued a corrigendum to its Integrated Annual Report for the 35th Annual General Meeting for the Financial Year 2024-25, in reference to its letter dated 6th September 2025. * Inadvertent typographical errors were identified in the Integrated Annual Report, which was distributed electronically to shareholders on 6th September 2025. * The corrections pertain to the Notes to the Notice: * Page 5 – Points 10 and 12: Clarifications regarding the appointment of Mr. Virendra G. Bhatt as Scrutinizer and the book closure period from 23rd September 2025 to 29th September 2025 (both days inclusive). * Page 8 – Point 16(i): The e-voting period end date was incorrectly stated as 28th September 2024 and has been corrected to 28th September 2025. The correct e-voting period begins on 26th September 2025 (09:00 AM) and ends on 28th September 2025 (05:00 PM), with the cut-off date for voting being 22nd September 2025. * The company has confirmed that these typographical errors do not affect the financial statements for the year ended 31st March 2025. * An updated version of the Integrated Annual Report and this corrigendum are available on the company's website.
What to do with a filing like this
Aarey Drugs & Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarey Drugs & Pharmaceuticals Limited. Read the original for the full detail.